Daniel Gregory
2025 Joint Meeting of the COSA ASM and IPOS Congress
Days
Tuesday, 11th November
Wednesday, 12th November
Thursday, 13th November
Friday, 14th November
Search
Speakers
Daniel Gregory
Abstracts this author is presenting:
Time to subsequent therapy in patients with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with patients receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
—
Afternoon tea, Poster session 1 & Exhibition
The role of platinum-free interval in advanced endometrial cancer treatment: a real-world study of 843 patients
—
Afternoon tea, Poster session 1 & Exhibition